Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial

Core Points - Anixa Biosciences, in collaboration with Moffitt Cancer Center, has received approval for an amendment to its clinical trial protocol for CAR-T therapy targeting ovarian cancer, allowing for a second dose and expanding eligibility to include additional tumor types [1][2][3] Group 1: Protocol Changes - The amendment permits eligible patients to receive a second dose of CAR-T therapy without needing individual IND submissions, enhancing treatment flexibility [2][3] - Enrollment now includes patients with sex cord-stromal tumors (SCSTs) and Sertoli Leydig cell tumors (SLCTs), broadening the scope of the trial [2] Group 2: Expert Commentary - Dr. Robert Wenham emphasized the importance of the amendment in advancing ovarian cancer treatment, highlighting the potential for additional benefits from a second dose [3] - Dr. Amit Kumar expressed excitement about the protocol amendment, viewing it as a significant step towards optimizing ovarian cancer treatment and improving patient outcomes [3] Group 3: Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes a novel CAR-T therapy for ovarian cancer developed in partnership with Moffitt Cancer Center [4] - The company also collaborates with Cleveland Clinic on vaccine development for breast and ovarian cancer, as well as other cancers, utilizing innovative immunization technologies [4]